Abstract 3896
Background
MCLA-128 is a novel bispecific antibody targeting HER2 and HER3 receptors with enhanced antibody-dependent cell-mediated cytotoxicity. No DLT was seen during dose escalation and the R2PD was 750 mg q3w. We report safety across solid tumor expansion indications, and efficacy in metastatic GC/GEJ patients (pts).
Methods
Safety, PK, immunogenicity and biomarkers were evaluated in heavily pretreated advanced metastatic cancer pts treated with MCLA-128, 750 mg q3w, 2-hr IV. Response (RECIST 1.1) and clinical benefit rate (CBR; CR + PR + SD ≥ 12 wks) were assessed in HER2-positive GC/GEJ pts who had progressed on trastuzumab.
Results
As of 15 Feb 2018, 100 pts were enrolled in the expansion cohorts, 97 of whom were treated. Mean age was 58 ± 11 years, M/F: 26/74, ECOG PS 0/1: 36/63 (1 missing). Pts received a median of 2 MCLA-128 cycles (range 1 - 27). Common related AEs were infusion-related reactions (19%), diarrhea (17%), asthenia/fatigue (15%), nausea (6%), and decreased appetite (5%). Four (4%) pts had suspected related grade 3-4 AEs. No clinically significant LVEF decline (>10% from baseline and LVEF <50%) was seen. Mean T1/2 was ∼100 hr (n = 89). Steady state serum concentrations of MCLA-128 were achieved after 2 cycles. As of 25 Mar 2018, 25 GC/GEJ pts were evaluable for response, with a median 3 metastatic sites (range 1-6), and progression on 1-2 prior anti-HER2 agents. They received a median of 2 MCLA-128 cycles (range 1-17). 1 pt had a confirmed CR (8+ cy), 9 pts had SD (sustained: 4, 5, 6, 12, 17 cy). CBR was 24% (6/25 pts). Based on central analysis variable HER2 levels were observed by HER2 IHC, and HER2 amplification was confirmed by FISH in all CBR patients. 4 of the 6 CBR pts had HER2 IHC 3+.
Conclusions
MCLA-128 is very well tolerated with mainly grade 1/2 AEs. Promising single agent antitumor activity was seen in heavily pretreated GC/GEJ pts progressing on anti-HER2 therapy. Further clinical exploration of MCLA-128 in GC/GEJ pts is warranted.
Clinical trial identification
EudraCT: 2014-003277-42.
Legal entity responsible for the study
Merus NV.
Funding
Merus NV.
Editorial Acknowledgement
Dr Sarah MacKenzie, Oncology Therapeutic Development.
Disclosure
M. Alsina, A. Varga, A. Amatu, J.H.M. Schellens, P.O. Witteveen, V. Boni, V. Moreno: Institution participates in corporate-sponsored research (Merus NV). K. Bol, A. Lourbakos, M. Magin Ferrer, E. Wasserman: Employee: Merus NV.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract